Bhoomika Yogi

Bhoomika Yogi

Auto-generated profile, based on publicly available information

Bhoomika Yogi

Hygia Institute of Pharmaceutical Education and Research, Lucknow, India

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
KSKuldeep Singh
Kuldeep Singh
SMSamar Mujeeb
Samar Mujeeb
BYBhoomika Yogi
Bhoomika Yogi
VAVaseem Ahmad Ansari
Vaseem Ahmad Ansari
SSShweta Sinha
Shweta Sinha
Background: Tuberculosis (TB) is an acute or chronic infectious disease caused by several species of Mycobacterium, collectively called tubercle bacilli or Mycobacterium tuberculosis complex. Around 10 million people get sick with tuberculosis (TB) each year. TB is the second leading cause of death today after HIV/AIDS. A serious problem in the context of MDR-TB is the extensively drug-resistant TB, which is an important reason for the restricted chemotherapy in TB. Therefore, there is a need to explore new antitubercular (anti-TB) agents. Coumarin is an oxygencontaining heterocyclic compound and can be widely found in many natural products, and many of them display diverse biological activities. The wide spectrum of activities of coumarin molecules has intrigued the scientists to explore the natural coumarins and their synthetic derivatives for their potential as anti-TB drugs.Objective: The objective of this review is to emphasize important coumarin analogs with anti-TB activities and their structure-activity relationships (SAR) for designing better anti-TB agents.Method: Latest, authentic and published reports on various synthetic and natural coumarin derivatives and their anti-TB activities is being thoroughly studied and analyzed. The structural requirements of coumarins as anti-TB drugs have also been studied.Results: Collection and compilation of reports on various synthetic and natural coumarin derivatives and their anti-TB activities are being performed.Conclusion: The study provides the latest report on coumarin derivatives synthesized as anti-TB agent and whether their activity depends on structural changes or not.

27 August 2018 in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SGSujeet Kumar Gupta
Sujeet Kumar Gupta
PKPratik Khanal
Pratik Khanal
AKArun Kumar
Arun Kumar
NSNeha Srivastava
Neha Srivastava
BYBhumika Yogi
Bhumika Yogi
ASAnshuman Sinha
Anshuman Sinha
Background: Recently, pyrazole derivatives have shown significant anti-inflammatory activity. Non-steroidal anti-inflammatory drugs have the drawbacks of such as gastric irritation and gastric ulceration in treatment of inflammation. So the current study deals with the synthesis and pharmacological evaluation of a series of novel pyrazole derivatives as anti-inflammatory agents. Methods: A series of novel ethyl 5-(substituted)-1H-pyrazole-3-carboxylate (2a-j) were synthesized and evaluated for anti-inflammatory activity using carrageenan-induced inflammation in rat paw edema model. In the first step, diethyl oxalate react with acetophenone derivatives in presense of sodium ethoxide to form substituted ethyl-2,4-dioxo-4-phenyl butanoate derivatives as intermediate (1a-j). Further the treatment of suspension prepared from dioxo-esters with hydrazine hydrate in presence of glacial acetic acid yielded novel ethyl 5-(substituted)-1H-pyrazole-3-carboxylate (2a-j) derivatives. The structure of the final analogues (2a-j) has been confirmed on the basis of elemental analysis, IR, 1H NMR and mass spectra. Results: All the values of elemental analysis, FTIR, 1H NMR, and mass spectra were found to be prominent. The anti-inflammatory activity test revealed that Ethyl 5-(3,4-dimethoxyphenyl)-1H-pyrazole-3-carboxylate (2f) and ethyl 5-(2,3-dimethoxyphenyl)-1H-pyrazole-3-carboxylate (2e) exhibited significant anti-inflammatory activity as compared to control group. Conclusion: The results of the current study indicate that substitution at pyrazole scaffold could improve anti-inflammatory activity.

2 October 2026 in Current Nanomedicine
Verified
Journal Article
Closed access
PDF file
ASAman Kumar Singh
Aman Kumar Singh
SSSatya Prakash Singh
Satya Prakash Singh
SGSujeet Kumar Gupta
Sujeet Kumar Gupta
BYBhumika Yogi
Bhumika Yogi
Introduction: Fungal infections are a major public health concern globally, particularly in tropical and subtropical regions. High humidity, poor hygiene, and limited access to healthcare facilities increase the risk of fungal infection transmission. Conventional topical antifungal formulations, such as creams, gels, and ointments, have limited efficacy due to poor skin penetration, low bioavailability, rapid clearance from the site of application, and the stratum corneum barrier. These limitations may reduce treatment effectiveness and increase the risk of antifungal resistance. Methods: This review systematically summarizes the published literature on invasome-based drug delivery systems, focusing on their structure, composition, preparation methods, physicochemical characterization, and applications in antifungal therapy. Results: Invasomes are novel ultra-deformable lipid vesicles composed of phospholipids, ethanol, and terpenes. These components enhance vesicle flexibility and disrupt the lipid structure of the stratum corneum, thereby significantly increasing drug transdermal permeability. Compared with other vesicular systems, such as liposomes, ethosomes, and transferosomes, invasomes show superior deformability, permeability, and biocompatibility. The performance of invasomes depends mainly on parameters such as particle size, zeta potential, drug entrapment efficiency, and deformability. Invasome formulations containing antifungal agents, such as luliconazole, fluconazole, ketoconazole, clotrimazole, and terbinafine, have demonstrated improved drug delivery and therapeutic outcomes. Discussion: The high permeability of invasomes is attributed to their synergistic composition, which facilitates penetration into the deeper epidermal and dermal layers. Invasomes can be readily prepared on a large scale and can be incorporated into various topical formulations, making them promising carriers for topical antifungal therapy. However, challenges related to stability, safety, and regulatory approval still need to be addressed. Conclusion: Invasomes represent a promising strategy for improving topical antifungal drug delivery. Their enhanced permeability and drug retention can overcome the limitations of conventional formulations, supporting their potential for effective and targeted treatment of fungal infections.